About 50% of stem cell transplant patients develop GVHD. A clinical trial using a modified stem cell graft reduced this hazard to 9%.
Clinical team finds gut microbiota in cancer patients could predict the outcome of their stem cell transplantation
Manufacturing of clinical grade Tregs for cell based therapies
Stem cell transplantation is often the only option for patients who have certain blood cancers. Unfortunately, this last resort can sometimes bring more harm than good. Graft versus host disease (GVHD), is a common complication that affects 50% of transplant patients. GVHD is not an issue if the patient's own stem cells are transplanted back. However, GVHD can become an issue, sometimes fatal, when stem cells from another donor are used.